Project Grant R21AI176947
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $489,500 to The Children's Hospital of Philadelphia Research Institute on June 11, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855). This two-year project, which extends through May 31, 2027, focuses on developing novel sequencing methodologies and analytical pipelines to identify and characterize intact human immunodeficiency virus (HIV) reservoir cells...
- Summary Under a $234,292 Project Grant awarded September 13, 2025, by the Fogarty International Center (CFDA 93.989: International Research and Research Training), Impact Research and Development Organisation will develop and pilot test a multilevel, community-based intervention to reduce Pre-Exposure Prophylaxis (PrEP) stigma and increase PrEP uptake among adolescent girls and young women (AGYW) ages 15–24 in western Kenya. The project addresses a critical public health gap, as AGYW represent...
- Grant Award Summary The Scripps Research Institute received a $1.38 million Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective August 21, 2025, through July 31, 2030. The award supports systematic research aimed at engineering durable immunity through optimization of HIV vaccine parameters to drive long-lived plasma cell development. The research will examine three...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded UC San Diego a $812,427 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective August 1, 2025, through July 31, 2030. The award supports development of an HIV Molecular Epidemiology Dashboard designed to integrate de-identified and aggregated HIV sequence data with publicly available national HIV prevention and treatment data from the AIDSVu platform....
- Grant Award Summary The University of Florida received a $1.13 million Project Grant from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) to develop the Synchronized Agentic Prescriptive System for Improving Sequentially HIV Care Continuum (SYNAPSIS-HIV-CC). The award, effective April 1, 2026, through December 31, 2030, funds the development of an artificial intelligence (AI)-driven clinical decision support system designed to optimize...
- Project Grant Summary Massachusetts Institute of Technology received a $1.65 million project grant from the National Institute on Drug Abuse under the Drug Use and Addiction Research Programs (CFDA 93.279) awarded on July 15, 2025, with an anticipated completion date of March 31, 2030. The project, titled "Integration and Validation of Single-Cell Neuronal and Immune Molecular Responses in SUD and HIV," delivers advanced computational research analyzing genetic and molecular mechanisms...
- Grant Award Summary: High-Performance Computing for HIV Research Excellence The Infectious Diseases Institute (IDI) in Uganda received a $302,160 Project Grant awarded on July 1, 2025, through the Fogarty International Center's International Research and Research Training program (CFDA 93.989) to strengthen computational research infrastructure and capacity supporting HIV research and broader biomedical investigation. The primary deliverables include intensive technical training for four Ugandan...
- This Project Grant award in the amount of $431,712, funded by the National Institute of Allergy and Infectious Diseases under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to improve HIV testing among children under five in rural Uganda. The primary goal is to engage with traditional healers to facilitate HIV counseling and testing via oral swab antigen tests for this vulnerable pediatric population. The award supports two key activities: 1) determining barriers and...
- Federal Cooperative Agreement Summary The National Center for HIV/AIDS, under the Centers for Disease Control and Prevention (CDC), awarded a $5.075 million Cooperative Agreement (CFDA 93.084 - Prevention of Disease, Disability, and Death by Infectious Diseases) to The Regents of the University of Colorado, doing business as University of Colorado-Denver, for the project "Understanding Integrative Care and Support Pathways to Healthy Aging for Adults Aging with HIV" (PS24-039). The...
- Federal Grant Award Summary New York University School of Medicine received a $841,719 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective April 1, 2026 through March 31, 2031. The research initiative addresses HIV treatment monitoring by developing low-cost rapid antibody-based tests to complement polymerase chain reaction (PCR) viral load testing. The project...
A NOVEL APPROACH TO PINPOINT PREDISPOSED RECOMBINATION REGIONS IN HIV FOR A GLOBAL PROFILE OF HIV RECOMBINANTS' OCCURRENCE AND EVOLUTION - PROJECT SUMMARY/ABSTRACT OCCURRING MORE FREQUENT THAN POINT MUTATIONS, THE RECOMBINATION EVENTS IN HIV HAVE RESULTED IN EPIDEMIOLOGICALLY IMPORTANT FOUNDER STRAINS IN VARIOUS GEOGRAPHIC REGIONS AND CONTRIBUTE TO AT LEAST 20-30% OF GLOBAL HIV INFECTIONS. HOWEVER, AFTER 33 YEARS OF RECOGNIZING HIV RECOMBINATION, TWO CRITICAL QUESTIONS STILL REMAIN ELUSIVE AS TO HOW HIV RECOMBINATION EVENTS HAVE OCCURRED AND HOW TO PREDICT EMERGING RECOMBINANT CLUSTERS TO BETTER INFORM PUBLIC HEALTH DECISION MAKING. BASED ON NEARLY 20 YEARS OF HIV EXPERIENCE, WE BELIEVE THAT BOTH QUESTIONS RELATE TO THE FLAWS INHERENT IN THE CURRENT CLASSIFICATION SYSTEM FOR HIV RECOMBINANT FAMILIES (CRFS), WHICH HAS INADEQUATELY APPRECIATED THE RAPID VIRUS EVOLUTION WITHIN AND BETWEEN RECOMBINANT FAMILIES. AS A RESULT, THIS STATIC DEFINITION OF CRFS NOT ONLY CREATES A SMALL-SAMPLE-SIZE PROBLEM FOR MOST CRFS, BUT ALSO MAKES IT DIFFICULT TO TRACK VIRAL EVOLUTION IN A DYNAMIC MEANS; WHILE BOTH ISSUES ARE ESSENTIAL FOR PUBLIC HEALTH SURVEILLANCE AND FOR IMPROVED VACCINE AND ANTIVIRALS DESIGN TARGETING HIV RECOMBINANTS. IN THIS PROPOSED STUDY, OUR OBJECTIVES ARE TO: 1) STRATEGICALLY FULFILL THE INADEQUATE AND MISSING CRF INFORMATION TO OVERCOME THE SMALL- SAMPLE-SIZE PROBLEM CREATED BY THE CRF DEFINITION, AND 2) PROVIDE A GLOBAL PROFILE ALONG THE HIV GENOME ABOUT HIV'S RECOMBINATION OCCURRENCE AND EVOLUTION VIA PINPOINTING HIV PREDISPOSED RECOMBINATION REGIONS BASED ON THE ENRICHED CRF INFORMATION. OUR CENTRAL HYPOTHESIS IS THAT THE INADEQUATE AND MISSING CRF INFORMATION, WHICH ACCOUNTS FOR THE LIMITED SAMPLE SIZE FOR MOST CRFS AND THE LACK OF A DYNAMIC VIEW OF CRFS, CAN BE STRATEGICALLY FULFILLED BY ADDING INFORMATION FROM HIV FRAGMENT SEQUENCES (I.E., NON-FULL-LENGTH SEQUENCES) THAT CONSIST OF OVER 90% OF ALL PUBLISHED HIV DATA DEPOSITED IN GENBANK. OUR HYPOTHESIS IS BASED ON SEVERAL IMPORTANT LINES OF EVIDENCE, INCLUDING RESULTS FROM OUR STUDIES. OUR RATIONALE FOR THIS PROPOSED STUDY IS THAT FULFILLING THE INADEQUATE AND MISSING CRF INFORMATION WILL INCREASE OUR CAPABILITIES IN THE SURVEILLANCE AND TRACKING OF EXISTING HIV RECOMBINANTS AND FOR IMPROVED PREDICTION OF EMERGING HIV RECOMBINANTS' CLUSTERS. LEVERAGED BY OUR NEARLY 20 YEARS OF EXPERIENCE IN HIV DATA MINING, STATISTICAL METHOD DEVELOPMENT, STATISTICAL MACHINE LEARNING, AND STATISTICAL GENETICS, WE WILL DEVELOP AND VALIDATE TWO NEW METHODS IN THREE AIMS. BY THE END OF THIS PROPOSED PROJECT, WE EXPECT TO OBTAIN NEW METHODS AND NEW FINDINGS TO ADVANCE OUR UNDERSTANDING OF THE CRFS (E.G., RECOMBINATION MECHANISMS AND EVOLUTION) AND FOR IMPROVED PUBLIC HEALTH SURVEILLANCE FOR EXISTING AND EMERGING CRF CLUSTERS. FINALLY, OUR METHODS AND RESULTS WILL BE RELEASED FOR FREE TO FACILITATE OTHER VIRUSES' RESEARCH IN RECOMBINATION.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 12/11/24 | ||
| Not listed | $146.8k | 12/11/24 | ||
| Not listed | ($147k) | 12/11/24 | ||
| Not listed | $197.0k | 8/9/24 | ||
| Not listed | $197.0k | 8/9/24 |